IPO registrations (S-1, F-1) · Registrants
Enlivex Ltd.
- SEC CIK
- 1596812 · filings on EDGAR ↗
- Name on the registration
- Bioblast Pharma Ltd.
- Former names
- Enlivex Therapeutics Ltd. (2019–2026); Bioblast Pharma Ltd. (2016–2019); BIO BLAST PHARMA LTD. (2014–2016)
- Registration
- Form F-1, first filed 2014-02-07, last 2017-04-06; 2 initial registrations, 9 amendments
- Outcome
- Final prospectus filed 2014-07-31; declared effective 2014-07-30; withdrawal requested 2017-04-06
- Industry (SIC)
- Finance Services 6199
- Incorporated in
- L3
- Business address
- 37 DEREH MENACHEM BEGIN ST., 15TH FLOOR, Tel Aviv
- Ticker
- ENLV (Nasdaq)
- EDGAR entity type
- other
- Insiders and CEO pay
- Enlivex Ltd. on the corporate pages
Offering terms
- Proposed price range
- $11.00–$13.00 per share (F-1/A filed 2014-07-25)
- Final price
- $11.00 per share, within the range (424B4 filed 2014-07-31, an initial public offering)
- Shares sold
- 3,200,000
- Gross proceeds
- $35,200,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ORPN
- Lead underwriters
- Oppenheimer (1,440,000 shares); Roth Capital Partners (1,440,000 shares)
- Syndicate
- BTIG (320,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: BIO BLAST PHARMA LTD. EXACT (CIK (EXACT))
- SEC filer: Enlivex Ltd. EXACT (CIK (EXACT))
Filings 15
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2014-02-07 | F-1 | F-1 (foreign registration) | BIO BLAST PHARMA LTD. | 0001144204-14-006928 ↗ |
| 2014-03-17 | F-1/A | F-1/A (amendment) | BIO BLAST PHARMA LTD. | 0001144204-14-015894 ↗ |
| 2014-04-08 | F-1/A | F-1/A (amendment) | BIO BLAST PHARMA LTD. | 0001144204-14-021277 ↗ |
| 2014-07-08 | F-1/A | F-1/A (amendment) | BIO BLAST PHARMA LTD. | 0001144204-14-041824 ↗ |
| 2014-07-15 | F-1/A | F-1/A (amendment) | BIO BLAST PHARMA LTD. | 0001144204-14-042948 ↗ |
| 2014-07-25 | F-1/A | F-1/A (amendment) | BIO BLAST PHARMA LTD. | 0001144204-14-044906 ↗ |
| 2014-07-30 | EFFECT | EFFECT (declared effective) | BIO BLAST PHARMA LTD. | 9999999995-14-002300 ↗ |
| 2014-07-31 | 424B4 | 424B4 (final prospectus) | BIO BLAST PHARMA LTD. | 0001144204-14-046055 ↗ |
| 2015-08-12 | EFFECT | EFFECT (declared effective) | BIO BLAST PHARMA LTD. | 9999999995-15-002277 ↗ |
| 2017-02-24 | F-1 | F-1 (foreign registration) | Bioblast Pharma Ltd. | 0001144204-17-011003 ↗ |
| 2017-03-16 | F-1/A | F-1/A (amendment) | Bioblast Pharma Ltd. | 0001144204-17-014840 ↗ |
| 2017-04-04 | F-1/A | F-1/A (amendment) | Bioblast Pharma Ltd. | 0001144204-17-018878 ↗ |
| 2017-04-05 | F-1/A | F-1/A (amendment) | Bioblast Pharma Ltd. | 0001144204-17-019259 ↗ |
| 2017-04-06 | F-1/A | F-1/A (amendment) | Bioblast Pharma Ltd. | 0001144204-17-019315 ↗ |
| 2017-04-06 | RW | RW (withdrawal request) | Bioblast Pharma Ltd. | 0001144204-17-019411 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2014-07-25 | F-1/A | registration statement | $11.00–$13.00 | $6.07 | 3,333,333 | $20,233,331 | Nasdaq ORPN | 3 | primary document; range, price sentence, shares headline, proceeds computed, cover names 3 | document ↗ |
| 2014-07-31 | 424B4 | final prospectus | $11.00 | 3,200,000 | $35,200,000 | Nasdaq ORPN | 3 | primary document; price sentence, shares sentence, proceeds table, underwriting table 3, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Galamidi Einat | Officer | Chief Medical Officer | 1 | 2026 | |
| Hart Gili | Director | 1 | 2026 | ||
| Havron Avraham | Director | 1 | 2026 | ||
| Hershkovitz Oren | Officer | Chief Executive Officer | 1 | 2026 | |
| NOVIK SHAI A | Director | 1 | 2026 | ||
| Pomerantz Roger | Director | 1 | 2026 | ||
| Shlosberger Shachar | Officer | Chief Financial Officer | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2016-04-01 | BIO BLAST PHARMA LTD. | Pharmaceuticals | $6,699,999 | $6,699,999 | 4 | 1 |
| 2014-02-13 | BIO BLAST PHARMA LTD. | Pharmaceuticals | $4,750,000 | $4,750,000 | 28 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | BIO BLAST PHARMA LTD. | CT | Form D private offerings | CIK (EXACT) |
| SEC filer | Enlivex Ltd. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Finance Services:
- Big Digital Energy, Inc. PA
- HeartSciences Inc. TX
- Yungasi, Inc. NY
- BONK, INC. FL
- Binah Capital Group, Inc. NY
- Bluemount Holdings Ltd
- Twenty One Capital, Inc. TX
- MGT CAPITAL INVESTMENTS, INC. FL
- Marygold Companies, Inc. CA
- STERLING FINANCIAL SERVICES OF FLORIDA I INC FL
Interests: Finance Services · Finance